0       0

AMDA Long Term Care Medicine - 2012


B07 - Personalized Medicine: Just Sexy or Clinically Relevant?


Mar 9, 2012 11:00am ‐ Mar 9, 2012 12:00pm

Standard: $24.00

Description

Accreditation
The American Medical Directors Association (AMDA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement:
The American Medical Directors Association designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

AMDCP Credit Designation:
This session has been approved for a total of clinical 1.0 credit hours toward certification as a Certified Medical Director in Long Term Care (CMD).

Session Description:
The science of pharmacogenomics has made significant progress in the past decade since the mapping of The Human Genome, and many of these biomarkers and genetic tests have now been included on FDA-approved drug labeling. This knowledge, although in its infancy may promote safe and effective use of certain targeted medications by more accurately predicting an individual's drug response and tolerance to therapy. This session will present current literature addressing drug therapy for select therapeutic areas highlighting the applicability of pharmacogenomics. Ethical, social, legal, and economic challenges of translating pharmacogenomics into clinical practice will be discussed using case-based examples. What should the prescriber/healthcare professional know about this emerging science and its implication for geriatric medicine?

Learning Objectives(s):

  • Define the science of pharmacogenomics and briefly review the lessons from The Human Genome Project.
  • Identify the potential of pharmacogenomics in therapeutic clinical applications and decision making for medication management in older adults.
  • Describe the variability in the genetic polymorphisms for CYP450 liver enzymes using some specific case examples (warfarin testing, SSRIs and tamoxifen cotherapy, clopidogrel and PPIs cotherapy).
  • Enumerate the challenges (ethical, social, legal, and economic) facing the wide application of pharmacogenomic testing in older adults.


Speakers(s):
Manju T. Beier, PharmD, CGP

Disclosure(s):
Manju T. Beier, PharmD, CGP has no financial disclosures to report.

References(s):
Pharmacogenomics of adverse drug reactions: practical applications and perspectives. Becquemont L. Pharmacogenomics. 2009 Jun;10(6):961-9. Warfarin pharmacogenomics. Cavallari LH, Limdi NA. Curr Opin Mol Ther. 2009 Jun;11(3):243-51. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery. Gulseth MP, Grice GR, Dager WE. Am J Health Syst Pharm. 2009 Jan 15;66(2):123-33. Pharmacogenetics and adverse drug reactions. Meyer UA. Lancet. 2000 Nov 11;356(9242):1667-71. Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicine. Frueh FW. Pharmacogenomics. 2009 Jul;10(7):1077-81. Drug-drug interaction between clopidogrel and the proton pump inhibitors. Norgard NB, Mathews KD, Wall GC. Ann Pharmacother. 2009 Jul;43(7):1266-74. Epub 2009 May 26. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. Desmarais JE, Looper KJ. J Clin Psychiatry. 2009 Dec;70(12):1688-97.

Speaker(s):

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content